首页> 外文期刊>Beverages >The Effect of Dietary Supplementation of Green Tea Catechins on Cardiovascular Disease Risk Markers in Humans: A Systematic Review of Clinical Trials
【24h】

The Effect of Dietary Supplementation of Green Tea Catechins on Cardiovascular Disease Risk Markers in Humans: A Systematic Review of Clinical Trials

机译:膳食补充绿茶儿茶素对人类心血管疾病危险标志物的影响:临床试验的系统评价

获取原文
获取外文期刊封面目录资料

摘要

Green tea catechins (GTCs) are secondary plant metabolites that have been associated with health benefits in human trials. As such, they have the potential to reduce cardiovascular disease (CVD) risk; however, results are not consistent. This systematic review of the published data assessed the putative effect of GTCs supplementation on anthropometric, blood pressure, and biochemical measures associated with CVD risk. It was conducted in accordance with the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines exploring four major electronic databases (MEDLINE, Cochrane Library, Web of Science, and Scopus). Studies were included if they were published in peer-reviewed journals in English from 1990 until October 2015, and were human double-blind randomized and placebo-controlled trials (RCTs). From 122,428 articles initially identified, after two levels of screening, seven studies met the inclusion criteria. The review revealed consistent and significant ( p ≤ 0.05) reductions in body mass index (BMI), blood pressure and plasma lipids; however, this effect would have been less if between-group effects had been considered. The current evidence base also has considerable methodological limitations due to suboptimal statistical methods used in data analyses. Future research efforts must aim to rectify this paucity of evidence with well-designed and well-reported prospective studies.
机译:绿茶儿茶素(GTC)是植物的次生代谢产物,已在人体试验中与健康相关。因此,它们具有降低心血管疾病(CVD)风险的潜力;但是,结果不一致。对已发表数据的系统评价评估了补充GTC对与CVD风险相关的人体测量,血压和生化指标的推定作用。它是根据用于系统评价和荟萃分析(PRISMA)指南的首选报告项目进行的,该指南探索了四个主要的电子数据库(MEDLINE,Cochrane图书馆,Web of Science和Scopus)。如果研究在1990年至2015年10月间以英语发表在同行评审期刊上,并且是人类双盲随机和安慰剂对照试验(RCT),则将其纳入研究。在初步筛选的122,428篇文章中,经过两个筛选级别后,有七个研究符合纳入标准。审查显示,体重指数(BMI),血压和血脂水平一致且显着(p≤0.05)降低;但是,如果考虑到群体间的影响,这种影响会更小。由于数据分析中使用的次优统计方法,当前的证据基础也有相当多的方法学限制。未来的研究工作必须旨在通过精心设计和报告充分的前瞻性研究来纠正这种缺乏证据的情况。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号